Insilico Medicine Featured in Harvard Business School Case Study on Rentosertib

The page describes a 2021 co-development agreement between Insilico Medicine and Fosun Pharma for ISM8207, a QPCTL inhibitor for immuno-oncology, plus four additional discovery programs. The deal is listed as $6M plus a $7M upfront payment. The page does not describe the QPCTL program's candidate-nomination timeline in the 9-month figure from the old description; it does confirm the Fosun co-development scope and deal value.

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.